The company’s founder is Daniel Albahari who has an M.Sc. in Molecular Biochemistry and Genetics and an RAC (US-Regulatory Affairs) degree. Daniel founded the company in 2016 after gaining extensive experience as a regulatory affairs consultant.

Daniel is a regulatory affairs professional specializing in regulatory strategy, medical device and combination product submissions and in commercializing new products and technologies.

During his academic career, Daniel received the prestigious Boehringer Ingelheim Fonds Research Award as well as other professional recognitions. He has lectured on various regulatory topics and published several academic works.

Daniel has provided regulatory affairs services to many private and public companies in Israel, the EU and USA. He has undertaken substantial regulatory work in recent years for an impressive range of companies including Abic Teva, Vensica Medical, Sol-gel, Keystone Heart, Izun Pharma, Rekah Pharmaceuticals, Silenseed, Wize Pharma, Mileutis, Yissum Agritech of the Hebrew University of Jerusalem, Brainlab, Adaptive Airway Labs, Nueon, Proctor & Gamble, BioMimetic Therapeutics, Boston Scientific among many others.

The regulatory expertise of BIOREG is complemented, when necessary, by a team of highly talented experts who can be called upon to advise in diverse disciplines such as Clinical Trials, IP, Toxicology, Veterinary, Pharmacology, Reimbursement and other areas as required.